Relevance,RGD ID,Symbol,Name,LOD,P Value,Trait,Sub Trait,Chr,Start,Stop,Species,Annotations,Match,Type 1000,2306968,Anxrr23,Anxiety related response QTL 23,4.83,,reflex trait (VT:0001961),amplitude of the acoustic startle response (CMO:0001520),15,43097470,52831189,Rat,n/a,region,qtl 1000,1578647,Bmd17,Bone mineral density QTL 17,4,,femur mineral mass (VT:0010011),total volumetric bone mineral density (CMO:0001728),15,26381041,106550657,Rat,n/a,region,qtl 1000,1578646,Bmd18,Bone mineral density QTL 18,5.2,,femur mineral mass (VT:0010011),trabecular volumetric bone mineral density (CMO:0001729),15,26381041,106550657,Rat,n/a,region,qtl 1000,2293686,Bmd36,Bone mineral density QTL 36,7.4,0.0001,femur strength trait (VT:0010010),femoral neck ultimate force (CMO:0001703),15,39749557,79033707,Rat,n/a,region,qtl 1000,2293691,Bmd37,Bone mineral density QTL 37,6.6,0.0001,femur strength trait (VT:0010010),femur total energy absorbed before break (CMO:0001677),15,39749557,79033707,Rat,n/a,region,qtl 1000,2300173,Bmd62,Bone mineral density QTL 62,12.8,0.0001,lumbar vertebra mineral mass (VT:0010511),volumetric bone mineral density (CMO:0001553),15,17249641,62249641,Rat,n/a,region,qtl 1000,2300167,Bmd63,Bone mineral density QTL 63,5.9,0.0001,femur mineral mass (VT:0010011),volumetric bone mineral density (CMO:0001553),15,17249641,62249641,Rat,n/a,region,qtl 1000,10755503,Bp391,Blood pressure QTL 391,2.37,,arterial blood pressure trait (VT:2000000),systolic blood pressure (CMO:0000004),15,23778969,46825072,Rat,n/a,region,qtl 1000,5685002,Bss103,Bone structure and strength QTL 103,2.8,,tibia strength trait (VT:1000284),tibia total energy absorbed before break (CMO:0001736),15,15828242,60828242,Rat,n/a,region,qtl 1000,1578660,Bss19,Bone structure and strength QTL 19,4.3,,femur morphology trait (VT:0000559),bone trabecular cross-sectional area (CMO:0002311),15,26381041,106550657,Rat,n/a,region,qtl 1000,2293688,Bss29,Bone structure and strength QTL 29,5.31,0.0001,femur morphology trait (VT:0000559),femur midshaft cortical cross-sectional area (CMO:0001663),15,17249641,62249641,Rat,n/a,region,qtl 1000,8694427,Bw163,Body weight QTL 163,4.82,0.001,body lean mass (VT:0010483),lean tissue morphological measurement (CMO:0002184),15,16980907,61980907,Rat,n/a,region,qtl 1000,1582244,Bw79,Body weight QTL 79,4,0.0002,epididymal fat pad mass (VT:0010421),epididymal fat pad weight to body weight ratio (CMO:0000658),15,33219101,89640841,Rat,n/a,region,qtl 1000,2324620,Coatc3,Coat color QTL 3,,,coat/hair pigmentation trait (VT:0010463),pigmented coat/hair area to total coat/hair area ratio (CMO:0001810),15,21021342,52831189,Rat,n/a,region,qtl 1000,1582228,Epfw3,Epididymal fat weight QTL 3,4.1,0.0002,epididymal fat pad mass (VT:0010421),epididymal fat pad weight to body weight ratio (CMO:0000658),15,33219101,89640841,Rat,n/a,region,qtl 1000,1598828,Glom14,Glomerulus QTL 14,2.5,,kidney glomerulus morphology trait (VT:0005325),index of glomerular damage (CMO:0001135),15,41068094,86068094,Rat,n/a,region,qtl 1000,2317750,Glom26,Glomerulus QTL 26,4.3,,urine protein amount (VT:0005160),urine protein level (CMO:0000591),15,15492360,72568189,Rat,n/a,region,qtl 1000,1582251,Gluco24,Glucose level QTL 24,3.2,0.0008,blood glucose amount (VT:0000188),blood glucose level (CMO:0000046),15,10719191,55719191,Rat,n/a,region,qtl 1000,1582242,Gluco28,Glucose level QTL 28,3.3,0.0008,blood glucose amount (VT:0000188),blood glucose level area under curve (AUC) (CMO:0000350),15,33219101,89640841,Rat,n/a,region,qtl 1000,1582227,Gluco30,Glucose level QTL 30,3.6,0.0003,blood glucose amount (VT:0000188),absolute change in blood glucose level area under curve (CMO:0002034),15,33219101,89640841,Rat,n/a,region,qtl 1000,738017,Hcas7,Hepatocarcinoma susceptibility QTL 7,2.91,,liver integrity trait (VT:0010547),liver nonremodeling tumorous lesion volume to total liver volume ratio (CMO:0001464),15,2327877,53535766,Rat,n/a,region,qtl 1000,10401805,Kidm51,Kidney mass QTL 51,,,kidney mass (VT:0002707),both kidneys wet weight (CMO:0000085),15,3881131,48881131,Rat,n/a,region,qtl 1000,631273,Lecl2,Lens clarity QTL 2,,0.001,lens clarity trait (VT:0001304),age of onset/diagnosis of cataract (CMO:0001584),15,39480797,62596410,Rat,n/a,region,qtl 1000,2298549,Neuinf12,Neuroinflammation QTL 12,3.5,,nervous system integrity trait (VT:0010566),spinal cord beta-2 microglobulin mRNA level (CMO:0002125),15,1,62301382,Rat,n/a,region,qtl 1000,1300144,Rf23,Renal function QTL 23,3.61,,renal blood flow trait (VT:2000006),absolute change in renal vascular resistance (CMO:0001900),15,43097470,106550657,Rat,n/a,region,qtl 1000,1331729,Rf42,Renal function QTL 42,3.071,,kidney blood vessel physiology trait (VT:0100012),absolute change in renal blood flow rate (CMO:0001168),15,18093208,81255430,Rat,n/a,region,qtl 1000,61424,Scl1,Serum cholesterol level QTL 1,7.7,0.001,blood cholesterol amount (VT:0000180),serum total cholesterol level (CMO:0000363),15,18513913,88036354,Rat,n/a,region,qtl 1000,9590272,Scort14,Serum corticosterone level QTL 14,2.78,0.001,blood corticosterone amount (VT:0005345),plasma corticosterone level (CMO:0001173),15,16980907,61980907,Rat,n/a,region,qtl 1000,10054130,Srcrt8,Stress Responsive Cort QTL 8,2.18,0.0085,blood corticosterone amount (VT:0005345),plasma corticosterone level (CMO:0001173),15,28709741,73709741,Rat,n/a,region,qtl 1000,1582214,Stl21,Serum triglyceride level QTL 21,3.1,0.022,blood triglyceride amount (VT:0002644),serum triglyceride level (CMO:0000360),15,33219101,89640841,Rat,n/a,region,qtl 1000,7411725,Strs7,Sensitivity to stroke QTL 7,3.8,,cerebrum integrity trait (VT:0010549),percentage of study population developing cerebrovascular lesions during a period of time (CMO:0000932),15,42757241,56027084,Rat,n/a,region,qtl